&Partners’s Idexx Laboratories IDXX Stock Holding History

&Partners’s Portfolio IDXX Stock Details IDXX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.29M	Sell	6,313 -13	-0.2%	-$7.29K	0.01%	767
2026 Q1	$3.55M	Sell	6,326 -907	-13%	-$582K	0.02%	651
2025 Q4	$4.9M	Buy	7,233 +850	+13%	+$579K	0.03%	504
2025 Q3	$4.08M	Buy	6,383 +456	+8%	+$277K	0.03%	490
2025 Q2	$3.18M	Buy	5,927 +2,839	+92%	+$1.36M	0.02%	491
2025 Q1	$1.28M	Buy	3,088 +1,561	+102%	+$678K	0.01%	724
2024 Q4	$634K	Buy	1,527 +475	+45%	+$208K	0.01%	966
2024 Q3	$531K	Buy	+1,052	New	+$511K	0.01%	841

Other funds holding IDXX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BAMCO Inc New York $66.6B AUM 7.35% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

&Partners's IDXX Position: Q2 2026 in Review

&Partners reduced its Idexx Laboratories (IDXX) stake by 0.21% in Q2 2026, selling an estimated $7.29K and leaving 6,313 shares worth $3.29M. The position accounts for 0.01% of the portfolio, ranked #767.

&Partners first reported a position in IDXX in Q3 2024 and has held it in 8 quarters since. The position peaked at $4.9M in Q4 2025. 1,302 funds tracked by Wall St. Rank hold IDXX as of Q2 2026.

&Partners held 6,313 shares of Idexx Laboratories worth $3.29M as of Q2 2026.
&Partners sold 13 Idexx Laboratories shares in Q2 2026, an estimated $7.29K.
Idexx Laboratories made up 0.01% of &Partners's portfolio in Q2 2026, its #767 holding.
&Partners first reported a position in Idexx Laboratories in Q3 2024 and has held it in 8 quarters since.
&Partners's Idexx Laboratories position peaked at $4.9M in Q4 2025.
1,302 funds tracked by Wall St. Rank held Idexx Laboratories as of Q2 2026.

Based on &Partners's 13F filing for Q2 2026, filed 14 Aug 2026.